Search

Your search keyword '"Gomez-Roca C.A."' showing total 42 results
Start Over Author "Gomez-Roca C.A."
42 results on '"Gomez-Roca C.A."'

1. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Author

Gomez-Roca, C.A., Italiano, A., Le Tourneau, C., Cassier, P.A., Toulmonde, M., D’Angelo, S.P., Campone, M., Weber, K.L., Loirat, D., Cannarile, M.A., Jegg, A.-M., Ries, C., Christen, R., Meneses-Lorente, G., Jacob, W., Klaman, I., Ooi, C.-H., Watson, C., Wonde, K., Reis, B., Michielin, F., Rüttinger, D., Delord, J.-P., and Blay, J.-Y.

Published
2019
Full Text
View/download PDF

2. 33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020

Author

Ascierto, P.A., primary, Tang, H., additional, Dolfi, S., additional, Nyakas, M.S., additional, Svane, I-M., additional, Couselo, E. Muñoz, additional, Grob, J.J., additional, Gomez-Roca, C.A., additional, Sileni, V. Chiarion, additional, Peltola, K., additional, Larkin, J., additional, Melero, I., additional, Callahan, M., additional, Dummer, R., additional, Djidel, P., additional, Warad, D., additional, Lipson, E.J., additional, and Garnett-Benson, C., additional

Published
2023
Full Text
View/download PDF

6. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)

Author

Martin Romano, P., primary, Roubaud, G., additional, Lavaud, P., additional, Cabart, M., additional, Pages, A., additional, Vasseur, D., additional, Colomba, E., additional, Cousin, S., additional, Toulmonde, M., additional, Grellety, T., additional, Castel Ajgal, Z., additional, Chabanon, R., additional, Parpaleix, A., additional, Buzzatti, G., additional, Fizazi, K., additional, Gomez-Roca, C.A., additional, Italiano, A., additional, Loriot, Y., additional, and Postel-Vinay, S., additional

Published
2022
Full Text
View/download PDF

7. 781TiP AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors

Author

Italiano, A., primary, Coutzac Bergouignan, C., additional, Pasquier, D., additional, Rochigneux, P., additional, Sablin, M.P., additional, Gomez-Roca, C.A., additional, Ghiringhelli, F., additional, Metges, J-P., additional, Toulmonde, M., additional, Cousin, S., additional, Pernot, S., additional, Auzanneau, C., additional, Lortal, B., additional, Kind, M., additional, Sargos, P., additional, Batard, S., additional, Petit, A., additional, Gillon, P., additional, Albert, S., additional, and Pulido, M., additional

Published
2022
Full Text
View/download PDF

13. 906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck

Author

Hansen, A.R., primary, Gomez-Roca, C.A., additional, Lolkema, M.P., additional, Verlingue, L., additional, Italiano, A., additional, Spicer, J., additional, Steeghs, N., additional, Bauman, J.E., additional, Fayette, J., additional, Niu, J., additional, Prenen, H., additional, Dejardin, D., additional, Boetsch, C., additional, Kraxner, A., additional, Evers, S., additional, Vardar, T., additional, Keshelava, N., additional, Teichgräber, V., additional, and Bonomi, M., additional

Published
2021
Full Text
View/download PDF

14. 138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations

Author

Polito, M., Le Tourneau, C., DeMontfort, A., Cousin, S., Toulmonde, M., Gomez-Roca, C.A., Bourcier, K., Korakis, I., Bertucci, F., Mitry, E., Mazza, C., Cassier, P., Coutzac, C., Italiano, A., Attignon, V.K., Mayet, R., Perol, D., Sablin, M.P., Blay, J-Y., and Tredan, O.

Published
2023
Full Text
View/download PDF

16. 758P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial

Author

Saint-Ghislain, M., Abdeddaim, C., Chaltiel, R., Cousin, S., Gomez-Roca, C.A., Borel, C., Ghiringhelli, F., Vansteene, D., Bigot, F., Jeannot, E., Guerini Rocco, E., Frige, G., Mazzarella, L., Francisco, M., Legrand, F., Jimenez, M., Halladjian, M., Kamal, M., Cabarrou, B., and Le Tourneau, C.

Published
2023
Full Text
View/download PDF

17. 557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial

Author

Coutzac, C., Bigot, F., Vansteene, D., Dos Santos, M., Ghiringhelli, F., You, B., Lambert, A., Gomez-Roca, C.A., Abdeddaim, C., Neuzillet, C., Jeannot, E., Guerini Rocco, E., Frige, G., Mazzarella, L., Dupain, C., Kamal, M., Legrand, F., Jimenez, M., Filleron, T., and Le Tourneau, C.

Published
2023
Full Text
View/download PDF

18. 2406P Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma of the penis: Subgroup analysis of the PEVOsq basket trial

Author

Coquan, E., Gomez-Roca, C.A., Lambert, A., You, B., Vansteene, D., Bigot, F., Cousin, S., Ajgal, Z. Castel, Jeannot, E., Guerini Rocco, E., Frige, G., Mazzarella, L., Francisco, M., Servant, N., Halladjian, M., Kamal, M., Legrand, F., Jimenez, M., Cabarrou, B., and Le Tourneau, C.

Published
2023
Full Text
View/download PDF

19. 560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment

Author

Pedrazzoli, A.B. Azaro, primary, Moreno, V., additional, Gomez-Roca, C.A., additional, Even, C., additional, Cassier, P., additional, Guerrero, T.C. Hernandez, additional, de Miguel, M., additional, Korakis, I., additional, Purcea, D., additional, Roy, E., additional, Gollmer, K., additional, Riff, C., additional, Szyldergemajn, S.A., additional, and Calvo, E., additional

Published
2020
Full Text
View/download PDF

22. A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors

Author

Cassier, P., primary, Eberst, L., additional, Garin, G., additional, Courbebaisse, Y., additional, Terret, C., additional, Robert, M., additional, Frenel, J.-S., additional, Depil, S., additional, Delord, J.-P., additional, Perol, D., additional, Ray-Coquard, I.L., additional, Bidaux, A.-S., additional, Tabone-Eglinger, S., additional, Gilles-Afchain, L., additional, Treilleux, I., additional, Wang, Q., additional, Ducarouge, B., additional, Mehlen, P., additional, Blay, J.-Y., additional, and Gomez-Roca, C.A., additional

Published
2019
Full Text
View/download PDF

23. Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i)BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC)by patient (pt)subgroup.

Author

Moreno V., De Braud F., Gomez-Roca C.A., Markman B., Desai J., Varga A.I., Joshua A.M., Gelmon K., Luke J., Tabernero J., Azrilevich A., Basciano P., Wind-Rotolo M., Ishii Y., Liu Z., Curigliano G., Siu L.L., Carlino M.S., Patel S.P., Moreno V., De Braud F., Gomez-Roca C.A., Markman B., Desai J., Varga A.I., Joshua A.M., Gelmon K., Luke J., Tabernero J., Azrilevich A., Basciano P., Wind-Rotolo M., Ishii Y., Liu Z., Curigliano G., Siu L.L., Carlino M.S., and Patel S.P.

Abstract

Introduction & Objectives: Nivo (anti-PD-1)has shown durable responses and manageable safety (ORR, 19.6%; grade 3-4 treatment-related AEs [TRAEs], 18%)in advBC (Sharma et al. Lancet Oncol 2017), but prolonging survival in more pts requires additional approaches to overcome tumor evasion mechanisms. IDO1 allows tumor escape through kynurenine (KYN)production, which stimulates regulatory T cells and suppresses effector T-cell proliferation. Anti-PD-1 can upregulate IDO1, supporting the rationale for combining nivo with an IDO1i. BMS-986205 is a selective, potent, once-daily (QD), oral IDO1i that works early in the IDO1 pathway to reduce KYN production. BMS-986205 + nivo showed favorable safety and efficacy in heavily pretreated pts with select solid tumors (Luke et al. SITC 2017; NCT02658890). Updated safety across all tumor cohorts and efficacy in the immuno-oncology (I-O)-naive advBC cohort are reported. Material(s) and Method(s): Dose-escalation methods in this phase 1/2a study were previously described; during expansion, pts received BMS-986205 100 or 200 mg QD + nivo 240 mg IV Q2W or 480 mg IV Q4W. Objectives included safety and ORR by RECIST v1.1 (includes unconfirmed responses). Result(s): As of Mar 2018, 516 pts received BMS-986205 + nivo; 45% had >=2 prior regimens. TRAEs occurred in 57% of pts (grade 3-4, 12%), the most common being fatigue (15%)and nausea (12%); 19 pts (4%)discontinued (DC)due to TRAEs and 3 pts (<1%)died due to a TRAE (myocarditis, Stevens-Johnson syndrome, and hepatic failure). In all treated pts and in the advBC cohort (n=30), the frequency and severity of TRAEs and rate of DC due to TRAEs were lower with BMS-986205 100 vs 200 mg. Among the 27 pts with I-O-naive advBC, the ORR was 37% (3 CRs, 7 PRs)and the DCR was 56%, with a median duration of follow-up of 24 wk. Responses were deep and durable, with some lasting beyond DC; median duration of response was not reached (range, 16.1-51.7+ wk). ORR and DCR in select l-O-naive advBC pt subgr

Published
2019

24. BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).

Author

Gelmon K.A., Liu Z., Ishii Y., Wind-Rotolo M., Basciano P.A., Azrilevich A., Luke J.J., Tabernero J., Joshua A., Desai J., Varga A.I., Moreno V., Gomez-Roca C.A., Markman B., De Braud F.G., Patel S.P., Carlino M.S., Siu L.L., Curigliano G., Gelmon K.A., Liu Z., Ishii Y., Wind-Rotolo M., Basciano P.A., Azrilevich A., Luke J.J., Tabernero J., Joshua A., Desai J., Varga A.I., Moreno V., Gomez-Roca C.A., Markman B., De Braud F.G., Patel S.P., Carlino M.S., Siu L.L., and Curigliano G.

Abstract

Background: Nivo (antiPD-1) has shown durable responses and manageable safety (ORR, 19.6%; grade 3-4 treatment-related AEs [TRAEs], 18%) in advBC (Sharma et al. Lancet Oncol 2017), but prolonging survival in more pts requires additional approaches to overcome tumor evasion mechanisms. IDO1 allows tumor escape through kynurenine (KYN) production, which stimulates regulatory T cells and suppresses effector T-cell proliferation. Anti-PD-1 can upregulate IDO1, supporting the rationale for combining nivo with an IDO1i. BMS-986205 is a selective, potent, once-daily (QD) oral IDO1i that works early in the IDO1 pathway to reduce KYN production. BMS-986205 + nivo showed favorable safety and efficacy in heavily pretreated pts with select solid tumors (Luke et al. SITC 2017; NCT02658890). Updated safety across all tumor cohorts and efficacy in the immuno-oncology (I-O)naive advBC cohort are reported. Method(s): Dose-escalation methods in this phase 1/2a, open-label study were previously described; during expansion, pts received BMS-986205 100 or 200 mg QD + nivo 240 mg IV Q2W or 480 mg IV Q4W. Objectives included safety and ORR by RECIST v1. 1 (includes unconfirmed responses). Result(s): As of Mar 2018, 516 pts received BMS-986205 + nivo; 45% had >=2 prior regimens. TRAEs occurred in 57% of pts (grade 3-4, 12%), the most common being fatigue (15%) and nausea (12%); 19 pts (4%) discontinued due to TRAEs, and 3 pts ( < 1%) died due to a TRAE (myocarditis, Stevens-Johnson syndrome, and hepatic failure). In all treated pts and within the advBC cohort (n = 30), the frequency and severity of TRAEs and rate of discontinuation due to TRAEs was lower with the 100- vs 200-mg BMS-986205 dose. Among the 27 pts with I-Onaive advBC, with a median duration of follow-up of 24 wk, ORR was 37% (3 CRs, 7 PRs), and the DCR was 56%; ORR in pts with tumor PD-L1 >1% (Dako PD-L1 IHC 28-8 pharmDx assay; n = 14) vs < 1% (n = 10) was 50% vs 30%. Conclusion(s): BMS-986205 + nivo was well tolerated in hea

Published
2019

25. BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

Author

Varga A.I., De Braud F.G., Patel S.P., Carlino M.S., Siu L.L., Gomez-Roca C.A., Curigliano G., Liu Z., Ishii Y., Phillips P., Wind-Rotolo M., Basciano P.A., Azrilevich A., Gelmon K.A., Tabernero J., Luke J.J., Joshua A.M., Moreno V., Markman B., Desai J., Varga A.I., De Braud F.G., Patel S.P., Carlino M.S., Siu L.L., Gomez-Roca C.A., Curigliano G., Liu Z., Ishii Y., Phillips P., Wind-Rotolo M., Basciano P.A., Azrilevich A., Gelmon K.A., Tabernero J., Luke J.J., Joshua A.M., Moreno V., Markman B., and Desai J.

Abstract

Background: NIVO (anti-PD-1) has shown durable responses and manageable safety (ORR, 19.6%; grade 3-4 treatment-related AEs [TRAEs], 18%) in pts with advBC (Sharma P, et al. Lancet Oncol 2017), but prolonging survival in more pts requires additional approaches to overcome tumor evasion mechanisms. IDO1 allows tumor escape through kynurenine (KYN) production, which stimulates development of regulatory T cells and suppresses effector T-cell proliferation. Anti-PD-1 therapy can upregulate IDO1, supporting the rationale for combining NIVO with an IDO1i. BMS-986205 is a selective, potent, once-daily (QD), oral IDO1i that works early in the IDO1 pathway to reduce KYN production. BMS- 986205 + NIVO demonstrated a favorable safety profile and antitumor activity in heavily pretreated pts with select solid tumors (Luke J, et al. SITC 2017; NCT02658890). Updated safety across all tumor cohorts and efficacy in the advBC cohort are reported. Method(s): Dose-escalation methods of this phase 1/2a, open-label study were previously described; during expansion, pts received BMS-986205 100 or 200 mg QD + NIVO 240 mg IV Q2W or 480 mg IV Q4W. Objectives included safety and ORR by RECIST v1.1 (includes unconfirmed [u] responses). Prior IO therapy was permitted in the advBC cohort. Result(s): As of Dec 15, 2017, 434 pts received BMS-986205 + NIVO. TRAEs were reported in 51% of pts (grade 3-4, 12%), the most common being fatigue (13%) and nausea (10%); 16 pts (4%) discontinued due to TRAEs, and 1 pt died due to a TRAE (myocarditis). With a median follow-up of 17 wk (range, 4-53), the ORR among 29 pts with advBC was 34% (1 u CR, 9 PRs [1 u]), and the disease control rate (DCR) was 48%. Of 29 pts, 26 had no prior IO therapy; ORR in these pts was 38% (1 u CR, 9 PR [1 u]), and the DCR was 54%. ORR in pts with tumor PD-L1 >= 1% (Dako PD-L1 IHC 28-8 pharmDx assay; n = 15) vs < 1% (n = 11) was 47% vs 27%. Conclusion(s): BMS-986205 + NIVO was well tolerated, with a safety profile similar to that o

Published
2019

26. Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup

Author

Moreno, V., primary, Luke, J., additional, Gelmon, K., additional, Joshua, A.M., additional, Varga, A.I., additional, Desai, J., additional, Markman, B., additional, Gomez-Roca, C.A., additional, De Braud, F., additional, Patel, S.P., additional, Carlino, M.S., additional, Siu, L.L., additional, Curigliano, G., additional, Liu, Z., additional, Ishii, Y., additional, Wind-Rotolo, M., additional, Basciano, P., additional, Azrilevich, A., additional, and Tabernero, J., additional

Published
2019
Full Text
View/download PDF

28. Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)

Author

Melero, I., primary, Castanon Alvarez, E., additional, Mau-Sorensen, M., additional, Lassen, U.N., additional, Lolkema, M.P., additional, Robbrecht, D.G., additional, Gomez-Roca, C.A., additional, Martin-Liberal, J., additional, Tabernero, J., additional, Ros, W., additional, Ahmed, S., additional, Isambert, N., additional, Piper Lepoutre, H., additional, Boetsch, C., additional, Charo, J., additional, Evers, S., additional, Teichgräber, V., additional, and Schellens, J.H.M., additional

Published
2018
Full Text
View/download PDF

29. First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population

Author

Gomez-Roca, C.A., primary, Garralda-Cabanas, E., additional, Cruzalegui, F., additional, Ausseil, F., additional, Zorza, G., additional, Delfour, O., additional, Besse, J., additional, Akla, B., additional, Gautier, S., additional, Adam, J., additional, Lacroix-Triki, M., additional, Passioukov, A., additional, Roche, R., additional, Pavlyuk, M., additional, and Massard, C., additional

Published
2018
Full Text
View/download PDF

32. 1116 - Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup

Author

Moreno, V., Luke, J., Gelmon, K., Joshua, A.M., Varga, A.I., Desai, J., Markman, B., Gomez-Roca, C.A., De Braud, F., Patel, S.P., Carlino, M.S., Siu, L.L., Curigliano, G., Liu, Z., Ishii, Y., Wind-Rotolo, M., Basciano, P., Azrilevich, A., and Tabernero, J.

Published
2019
Full Text
View/download PDF

36. 31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts

Author

Toulmonde, M., primary, Le Tourneau, C., additional, Cropet, C., additional, Italiano, A., additional, Bertucci, F., additional, Ray-Coquard, I., additional, Tredan, O., additional, Cassier, P., additional, Seigne, C., additional, De la Fouchardiere, C., additional, Flechon, A., additional, Desseigne, F., additional, Frappaz, D., additional, Gomez-Roca, C.A., additional, Heudel, P.E., additional, You, B., additional, Jaouen, L., additional, Bernardin, M., additional, Perol, D., additional, and Blay, J.Y., additional

Published
2015
Full Text
View/download PDF

37. 444 Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinum-refractory epithelial ovarian cancer (EOC). Preliminary results of a Phase I dose-escalation study

Author

Le Tourneau, C., primary, Ray-Coquard, I., additional, Isambert, N., additional, Gomez-Roca, C.A., additional, Cassier, P., additional, Sablin, M.P., additional, Ruits, E., additional, Gavillet, B., additional, Zanna, C., additional, Fumuleau, P., additional, and Delord, J.P., additional

Published
2014
Full Text
View/download PDF

38. Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study

Author

Gomez-Roca, C.A., primary, Delord, J., additional, Robert, C., additional, Hidalgo, M., additional, von Moos, R., additional, Arance, A., additional, Elez, E., additional, Michel, D., additional, Seroutou, A., additional, Demuth, T., additional, and Tabernero, J., additional

Published
2014
Full Text
View/download PDF

39. Continuous Infusion of Cilengitide with Radio-Chemotherapy in Stage III Nsclc: a Phase I Study

Author

Moyal, E.L. Cohen-Jonathan, primary, Massabeau, C., additional, Filleron, T., additional, Modesto, A., additional, Bachaud, J., additional, Rouquette, I., additional, Dierickx, L., additional, Aziza, R., additional, Bigay-Gamé, L., additional, Plat, G., additional, Mounier, M., additional, Gomez-Roca, C.A., additional, Delord, J., additional, and Mazieres, J., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results